Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC

NCT ID: NCT06998758

Last Updated: 2025-12-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-11-11
• Study Completion Date: 2028-12-31

Brief Summary

Cancer-associated anorexia, a debilitating condition characterized by progressive appetite loss in oncology patients, contributes to pancytopenia, sarcopenia, and adipose tissue depletion. Megestrol acetate (MA) improves appetite and promotes weight gain through multiple mechanisms, playing a crucial role in the nutritional management of cancer patients. Total mesorectal excision (TME) following neoadjuvant chemotherapy has become the standard treatment strategy for patients with locally advanced colorectal cancer (LACRC). Despite its oncological benefits, neoadjuvant chemotherapy frequently induces grade ≥2 gastrointestinal toxicities (including nausea, emesis, and diarrhea) that exacerbate malnutrition through appetite suppression and negative energy balance. Previous studies have demonstrated that combining MA with first-line maintenance chemotherapy in patients with metastatic colorectal cancer significantly improves appetite, increases body weight, enhances quality of life, and improves prognosis. However, the safety and efficacy of MA during the neoadjuvant treatment phase of LACRC remain unclear. This multicenter, randomized controlled clinical trial aims to evaluate the effects of MA on chemotherapy--related weight loss, anorexia, nutritional status, and chemotherapy tolerance in patients with LACRC undergoing neoadjuvant chemotherapy. Additionally, this study will assess the safety profile of MA in this clinical setting.

Detailed Description

This clinical trial is an open-label, prospective, multicenter, randomized study. The aims of this study are to evaluate the effects of megestrol acetate (MA) on ameliorating neoadjuvant chemotherapy-related weight loss, anorexia, nutritional deterioration, andChemotherapy-related adverse events in patients with locally advanced colorectal cancer (LACRC), while comprehensively assessing its safety profile. Eligible participants will be randomly assigned in a 1:1 ratio to either the experimental group or the control group. Participants in the experimental group will receive 6 cycles of neoadjuvant chemotherapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) administered every 14 days, combined with oral MA suspension at a dose of 625 mg/day. MA treatment will be maintained until the completion of neoadjuvant chemotherapy. Participants in the control group will receive 6 cycles of the mFOLFOX6 neoadjuvant chemotherapy regimen without concurrent administration of MA. Subjects in both the experimental and control groups will undergo radical surgical treatment after completing the neoadjuvant therapy. Those achieving pCR based on postoperative pathology will be regularly followed up according to the follow-up protocol. Participants who do not achieve pCR will receive six cycles of adjuvant therapy after surgery, followed by regular follow-up assessments as outlined in the protocol after completing the final cycle of adjuvant therapy. The primary outcome of this study is the incidence of weight loss (defined as >5% body weight reduction during neoadjuvant therapy). Secondary objectives include: 1) Appetite evaluation; 2) Nutritional parameter dynamics; 3) Quality of life (QoL) assessment with the EORTC QLQ-C30 questionnaire; 4) Incidence of neoadjuvant chemotherapy-related adverse events; 5) Oncological response; 6) Surgical morbidity; 7) Postoperative recovery metrics: time to first flatus/bowel movement, length of postoperative hospitalization, and 30-day readmission rates; 8) Survival outcomes: 1-year disease-free survival (DFS), Overall survival (OS).

Conditions

Neoadjuvant Chemotherapy; Weight Loss

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

mFOLFOX6 + Megestrol Acetate

Patients from experimental group receive six cycles of neoadjuvant chemotherapy with mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin calcium 400 mg/m², fluorouracil 400 mg/m², and fluorouracil 2400 mg/m² continuous infusion over 48 hours on day 1) every 2 weeks and megestrol acetate at 625 mg/day by oral until the end of neoadjuvant chemotherapy.

Group Type: EXPERIMENTAL

Megestrol Acetate

Intervention Type: DRUG

Oral megestrol acetate at 625 mg/day is given from the beginning to the end of neoadjuvant chemotherapy.

mFOLFOX6

Patients from this group receive six cycles of neoadjuvant chemotherapy with mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin calcium 400 mg/m², fluorouracil 400 mg/m², and fluorouracil 2400 mg/m² continuous infusion over 48 hours on day 1) every 2 weeks

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Megestrol Acetate

Oral megestrol acetate at 625 mg/day is given from the beginning to the end of neoadjuvant chemotherapy.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Adult males and females aged between 18 and 75 years old.
• Histologically confirmed colorectal adenocarcinoma.
• Immunohistochemistry showing pMMR or MSI status determined as MSS.
• Clinical stage cTxN1-2M0, with or without MRF positivity, and with or without EMVI positivity.
• ECOG performance status 0-1, with a life expectancy of ≥6 months.
• Deemed suitable for preoperative mFOLFOX6 neoadjuvant chemotherapy following multidisciplinary team discussion.
• Written informed consent has been obtained from the patients.

Exclusion Criteria

• Patients with cardiac arrhythmias requiring anti-arrhythmic treatment (excluding β-blockers or digoxin), symptomatic coronary artery disease or myocardial ischemia (myocardial infarction within the past 6 months), or congestive heart failure greater than NYHA Class II.
• Patients with poorly controlled severe hypertension.
• Patients with a history of HIV infection or active chronic hepatitis B or C (with high-copy viral DNA).
• Patients with active tuberculosis (TB) who are receiving anti-tuberculosis treatment or have received anti-tuberculosis treatment within 1 year prior to screening.
• Patients with other active severe clinical infections (per NCI-CTC v.5.0).
• Patients who have previously received chemotherapy.
• Patients with a history of seizures requiring treatment (e.g., steroids or anti-epileptic therapy).
• Patients with drug abuse or medical, psychological, or social conditions that may interfere with study participation or outcome assessment.
• Patients with a known or suspected allergy to the study drug or any agents administered in relation to the trial.
• Patients with any unstable condition that may jeopardize patient safety or compliance.
• Pregnant or breastfeeding women, or fertile women not using adequate contraception.
• Patients who refuse to sign the informed consent form.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Jun Huang

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jun Huang, PhD.

Role: PRINCIPAL_INVESTIGATOR

Sun Yat-sen University

Locations

The Sixth Affiliated Hospital of Sun-Yat sen University

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jun Huang, PhD.

Role: CONTACT

huangj97@mail.sysu.edu.cn

+86-13926451242

Facility Contacts

Jun Huang, MD.

Role: primary

huangj97@mail.sysu.edu.cn

+86-13926451242

Other Identifiers

E2025078

Identifier Type: -

Identifier Source: org_study_id